Tel：028-88610620
Email：pr@keymedbio.com/BD@keymedbio.com
为确保高效、及时地生产及供应高质且可负担的抗体药物，康诺亚一直致力于提高内部生产能力。我们正在建设新生产基地，预计2022年6月一期工程投入使用，为我们提供额外的16,000L产能。预计项目全部建成后，将成为中国西部地区产能最大的抗体药物生产基地。
Company Profile Management Team Milestones Corporate Culture
R&D Center Pipeline Manufacturing Park Cooperation Expanded Access Policy
Corporate Governance Information Disclosure Financial Reports Stock Information IR Calendar Investor Presentations Email Alerts IR Contact
Latest News Media
Culture & Benefits
Contact Information Consultation Legal Statement Privacy
Tel：028-88610620
Email：pr@keymedbio.com/BD@keymedbio.com
蜀ICP备2022006281号